Investor Presentaiton
Q2 reported growth was up 10%, with -3%-points impact from the
Atos Medical acquisition and -1%-point negative currency effect
5,502
Q2 2022/23 Revenue development (DKKm)
453
558m DKK
155
-50
6,061
Reported
revenue Q2
2021/22
Organic growth
(constant
currencies)
Acquired
growth
Currency effect
Reported
revenue Q2
2022/23
Growth
8.2%
2.8%
-0.9%
10.1%
•
Q2 2022/23 highlights
Organic growth was 8% or DKK 453 million, driven by:
•
•
•
•
•
Continued solid momentum in Chronic Care across regions,
excluding China
China detracted from Ostomy Care growth due to COVID-19,
as expected
Continence Care continued to be impacted by backorders in
Collecting Devices
Voice & Respiratory Care delivered solid growth driven by
both Laryngectomy and Tracheostomy
Strong Q2 in Wound & Skin Care driven by solid momentum
in Wound Care Europe, including benefit from a low baseline
Continued strong momentum in Interventional Urology with
broad-based growth, led by the US Men's Health business
Acquired revenue contributed 3%-points to reported growth or DKK
155 million (1 month impact from the Atos Medical acquisition)
Foreign exchange rates had a negative impact of DKK 50 million or
-1%-point on reported growth, mainly related to depreciation of the
GBP and several emerging markets currencies against DKK
11
ColoplastView entire presentation